Stock Market buffalonews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from buffalonews.com Daily Mail and Mail on Sunday newspapers.
The oral JAK inhibitor is for adults with moderately to severely active Crohn s disease whose condition failed to respond adequately or who can t tolerate one or more TNF inhibitors.
Reports First-Quarter Diluted EPS of $0.13 on a GAAP Basis, a Decrease of 94.8 Percent; Adjusted Diluted EPS of $2.46, a Decrease of 22.2 Percent; These.
25.04.2023 - -In EMERALD-1 Phase 2a trial in patients with ulcerative colitis, MORF-057 meets primary endpoint and demonstrates clinically meaningful improvements across secondary and exploratory measures with no safety signal observed- -EMERALD-2 Phase 2b .